Ozempic May Lower Addiction Risk, New BMJ Study Shows
In a significant finding for patients managing type 2 diabetes, a new study published in the BMJ suggests that GLP-1 drugs like Ozempic may lower the risk of addiction. Researchers analyzed electronic health records from more than 600,000 veterans treated through the United States Department of Veterans Affairs, comparing those newly prescribed GLP-1 receptor agonists to those started on SGLT2 inhibitors such as empagliflozin and dapagliflozin. This Ozempic addiction risk research highlights potential benefits beyond blood sugar control, though causation remains unproven.
Study Design and Methodology
Prior animal studies had suggested GLP-1 drugs might reduce cravings and lower relapse risk in substance use. Large-scale analyses of health records hinted at similar patterns in humans. Building on this, the BMJ study employed "target trial emulation," a rigorous method that structures observational data to mimic a randomized controlled trial (RCT) as closely as possible.
In an RCT, participants are randomly assigned to treatment or control groups, ensuring similarity except for the intervention. Observational studies, however, can't fully eliminate confounding factors like unmeasured differences in age, weight, or health conditions. Target trial emulation minimizes these risks but still shows associations, not definitive causation. The study followed participants for up to three years, addressing key questions about new and existing substance use disorders (SUDs).
Key Findings for New Substance Use Disorders
Among people without a prior SUD, starting a GLP-1 drug was linked to a 14% overall reduced risk of developing new substance use disorders, including alcohol, cannabis, cocaine, nicotine, and opioids. Those on GLP-1s were less likely to develop one across every substance category examined. This translated to roughly 1-6 fewer cases per 1,000 people over three years.
Outcomes for Existing Substance Use Disorders
For individuals with an existing SUD, GLP-1 use was associated with a 26% reduction in substance-related hospital admissions. Better outcomes held across every measure, amounting to around 1-10 fewer events per 1,000 people over three years. These consistent patterns across multiple substances and outcomes strengthen the signal, though they remain associations.
Understanding GLP-1 Drugs Like Ozempic
GLP-1 receptor agonists, such as Ozempic (semaglutide), are injectable medications primarily approved for type 2 diabetes management and weight loss. They mimic the glucagon-like peptide-1 hormone, which regulates blood sugar by stimulating insulin release, slowing gastric emptying, and reducing appetite. Ozempic's weekly dosing has made it popular for metabolic health.
Emerging research explores off-label benefits, including cardiovascular protection and now potential impacts on addiction. Preclinical data shows GLP-1s may modulate brain reward pathways, reducing dopamine-driven cravings for alcohol, nicotine, and opioids. This could explain the observed lower Ozempic addiction risk in the veteran cohort.
Comparison to SGLT2 Inhibitors
The study used SGLT2 inhibitors—empagliflozin (Jardiance) and dapagliflozin (Farxiga)—as the comparator. These oral drugs promote glucose excretion via urine, offering kidney and heart benefits with a strong safety profile. Unlike GLP-1s, SGLT2s lack direct evidence for addiction modulation, making them an ideal control for isolating potential GLP-1 effects in diabetes patients.
